tbuckley/cabot-search huggingface dataset:
Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: A prospective multi-institutional trial
Authors: Ivan Jambor, Janne Verho, Otto Ettala, Juha Knaapila, Pekka Taimen, Kari T. Syvänen, Aida Kiviniemi, Esa Kähkönen, Ileana Montoya Perez, Marjo Seppänen, Antti Rannikko, Outi Oksanen, Jarno Riikonen, Sanna Mari Vimpeli, Tommi Kauko, Harri Merisaari, Markku Kallajoki, Tuomas Mirtti, Tarja Lamminen, Jani Saunavaara, Hannu J. Aronen, Peter J. Boström
Journal: PLoS Medicine (2019)

Magnetic resonance imaging (MRI) combined with targeted biopsy (TB) is increasingly used in men with clinically suspected prostate cancer (PCa), but the long acquisition times, high costs, and inter-center/reader variability of routine multiparametric prostate MRI limit its wider adoption.The aim was to validate a previously developed unique MRI acquisition and reporting protocol, IMPROD biparametric MRI (bpMRI) (NCT01864135), in men with a clinical suspicion of PCa in a multi-institutional trial (NCT02241122). IMPROD bpMRI has average acquisition time of 15 minutes (no endorectal coil, no intravenous contrast use) and consists of T2-weighted imaging and 3 separate diffusion-weighed imaging acquisitions. Between February 1, 2015, and March 31, 2017, 364 men with a clinical suspicion of PCa were enrolled at 4 institutions in Finland. Men with an equivocal to high suspicion (IMPROD bpMRI Likert score 3-5) of PCa had 2 TBs of up to 2 lesions followed by a systematic biopsy (SB). Men with a low to very low suspicion (IMPROD bpMRI Likert score 1-2) had only SB. All data and protocols are freely available. The primary outcome of the trial was diagnostic accuracy-including overall accuracy, sensitivity, specificity, negative predictive value (NPV), and positive predictive value-of IMPROD bpMRI for clinically significant PCa (SPCa), which was defined as a Gleason score ≥ 3 + 4 (Gleason grade group 2 or higher). In total, 338 (338/364, 93%) prospectively enrolled men completed the trial. The accuracy and NPV of IMPROD bpMRI for SPCa were 70% (113/161) and 95% (71/75) (95% CI 87%-98%), respectively. Restricting the biopsy to men with equivocal to highly suspicious IMPROD bpMRI findings would have resulted in a 22% (75/338) reduction in the number of men undergoing biopsy while missing 4 (3%, 4/146) men with SPCa. The main limitation is uncertainty about the true PCa prevalence in the study cohort, since some of the men may have PCa despite having negative biopsy findings.IMPROD bpMRI demonstrated a high NPV for SPCa in men with a clinical suspicion of PCa in this prospective multi-institutional clinical trial.ClinicalTrials.gov NCT02241122.
Modulation of tumor-derived exosomes for an efficient cancer vaccine
Authors: Jung-Ah Cho, Dong-Jun Yeo, Yong-Nyun Kim, Chul-Woo Kim
Journal: Cancer Research (2005)

3443  Exosomes are small membrane vesicles secreted from a various kinds of cells including hematopoietic cells, normal epithelial cells and some tumor cells. Like APC-derived exosomes, tumor-derived exosomes also possess the potential of immunologic stimulants because they harbor native tumor antigens as well as immunologically significant molecules like MHC class I and Hsc70. Nevertheless, tumor-derived exosomes can possess tolerogenic properties because of characteristics of tumor cells on their own. Therefore, we attempted to generate more immunostimulatory tumor-derived exosomes. First, we introduced a common tumor antigen MUC1 into tumor cell lines to make a broadly-applicable cancer vaccine. The data showed that exosomes from the trasnduced tumor cells harbored MUC1 and produced MUC1-specific anti-tumor effect in vivo. Secondly, we conjugated exosomes to oxidized mannan in order to augment a possibility to be targeted to dendritic cells and observed that mannan conjugation to exosomes efficiently enhanced internalization of exosomes by antigen-presenting cells. Thirdly, tumor cells were heat-treated to recruit more heat shock proteins into exosomes, which increased immune stimulus can be expected. During the recovery times after heat shock, inducible Hsp70 were highly expressed and appeared at the cellular surfaces. Simultaneously, exosomes from heat-treated tumor cells harbored the inducible form of Hsp70 and the quantity of exosomes were increased by heat treatment. These data suggest that exosomes can be modulated to become more immunogenic and may represent a first demonstration of modulated tumor-derived exosomes in using in cancer therapy.
Katie’s new face: transplant photo is shortlisted for Wellcome prize
Authors: Elisabeth Mahase
Journal: BMJ (2019)

Lynn Johnson/Wellcome

Silence fills the room as the large team of medical professionals regard the face they have just surgically removed from a donor. This will soon be Katie’s face. At 21, Katie, who suffered a self inflicted gunshot wound at age 18, is the youngest person to receive a full face transplant.

Over 30 hours the team …
The Next Stage of Buprenorphine Care for Opioid Use Disorder
Authors: Robert Sherrick
Journal: Annals of Internal Medicine (2019)

Letters4 June 2019The Next Stage of Buprenorphine Care for Opioid Use DisorderRobert Sherrick, MDRobert Sherrick, MDCommunity Medical Services, Kalispell, Montana (R.S.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L19-0143 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Martin and colleagues (1) make important observations about the next stage of buprenorphine care for opioid use disorder. This new paradigm suggests that medication for addiction treatment (MAT) should be considered to have various levels of intensity similar to how the American Society of Addiction Medicine criteria classify behavioral treatments for substance use disorders. These criteria (2) start with level 1 (outpatient counseling) and increase to level 2 (intensive outpatient services) and level 3 (residential and inpatient services).In terms of MAT, the lowest level of care would involve a patient on a stable dose of buprenorphine ...References1. Martin SA, Chiodo LM, Bosse JD, Wilson A. The next stage of buprenorphine care for opioid use disorder. Ann Intern Med. 2018;169:628-35. [PMID: 30357262]. doi:10.7326/M18-1652 LinkGoogle Scholar2. Mee-Lee D, eds. The ASAM Criteria: Treatment Criteria for Addictive, Substance-Related, and Co-Occurring Conditions. 3rd ed. Carson City, NV: The Change Companies; 2013. Google Scholar Author, Article, and Disclosure InformationAffiliations: Community Medical Services, Kalispell, Montana (R.S.)Disclosures: The author has disclosed no conflicts of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L19-0143. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoThe Next Stage of Buprenorphine Care for Opioid Use Disorder Stephen A. Martin , Lisa M. Chiodo , Jordon D. Bosse , and Amanda Wilson The Next Stage of Buprenorphine Care for Opioid Use Disorder Mark H. Duncan , Anna D. Ratzliff , Diane M. Powers , Caleb J. Banta-Green , and Andrew J. Saxon The Next Stage of Buprenorphine Care for Opioid Use Disorder Stephen A. Martin , Lisa M. Chiodo , Jordon D. Bosse , and Amanda Wilson The Next Stage of Buprenorphine Care for Opioid Use Disorder Barbara Scolnick The Next Stage of Buprenorphine Care for Opioid Use Disorder Herbert Malinoff Metrics 4 June 2019Volume 170, Issue 11Page: 820KeywordsConflicts of interestDisclosureInpatientsOpioid addictionOpioidsOutpatientsPatients ePublished: 4 June 2019 Issue Published: 4 June 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Controlling Matter at the Molecular Scale with DNA Circuits
Authors: Dominic Scalise, Rebecca Schulman
Journal: Annual Review of Biomedical Engineering (2019)

In recent years, a diverse set of mechanisms have been developed that allow DNA strands with specific sequences to sense information in their environment and to control material assembly, disassembly, and reconfiguration. These sequences could serve as the inputs and outputs for DNA computing circuits, enabling DNA circuits to act as chemical information processors to program complex behavior in chemical and material systems. This review describes processes that can be sensed and controlled within such a paradigm. Specifically, there are interfaces that can release strands of DNA in response to chemical signals, wavelengths of light, pH, or electrical signals, as well as DNA strands that can direct the self-assembly and dynamic reconfiguration of DNA nanostructures, regulate particle assemblies, control encapsulation, and manipulate materials including DNA crystals, hydrogels, and vesicles. These interfaces have the potential to enable chemical circuits to exert algorithmic control over responsive materials, which may ultimately lead to the development of materials that grow, heal, and interact dynamically with their environments.
Abstract O.44: Infliximab For Kawasaki Disease Patients Who Did Not Respond To The Initial Therapy : A Japanese Nationwide Surveillance
Authors: Tohru Kobayashi, Shinichi Takatsuki, Tsutomu Saji, Tomoyoshi Sonobe, Shunichi Ogawa, Hirotaro Ogino, Yosikazu Nakamura, Kenji Hamaoka
Journal: Circulation (2015)

Backgrounds: In Japan, infliximab (IFX) has been used in patients with Kawasaki disease (KD) who did not respond to initial treatment. However, nationwide surveillance of the IFX for KD patients has not been reported. The objective of the present study is to reveal epidemiological and clinical features of KD patients treated with IFX. Method: This retrospective observational study was conducted from 2007 to 2013. We sent a questionnaire to members of Japanese Society of Kawasaki disease annually and collected demographic data and clinical outcomes of KD patients treated with IFX. A total of 315 patients (208 boys and 107 girls, age at onset 37±25 months, illness days of initial treatment 4.3±1.2) from 46 hospitals were identified and analyzed in the present study. Results: No patients received IFX as initial treatment. Over 60% of the patients were treated with IFX as first or second line additional rescue treatment. After the IFX administration, 237 patients (75.7%) became afebrile within 24 hours and 82 patients (26.0%) treated additional rescue treatments subsequently. Before IFX administration, 55 patients already had coronary artery aneurysm exceeding 4mm and 69 patients were finally affected coronary artery aneurysm exceeding 4mm. Serum level of C reactive protein were significantly decreased after IFX administration (10.6±7.2 to 4.9±4.7, P&lt;0.001). Patients who required additional treatment after IFX showed significantly higher CRP levels before IFX compared to patients without additional treatment after IFX (12.3±8.3 vs. 10.0±6.7, P=0.049). Adverse events were observed in 50 patients (15.9%) which recovered spontaneously or after interventions. Conclusions: IFX therapy for Kawasaki disease patients who did not respond to the initial treatment would be well tolerated and play a certain role to improve clinical course.
Oncogenic NRG1 Fusions: A New Hope for Targeted Therapy in Pancreatic Cancer
Authors: Andrew J. Aguirre
Journal: Clinical Cancer Research (2019)

Approximately 8%-10% of pancreatic ductal adenocarcinoma cases are KRAS wild type. In a subset of these tumors, NRG1 gene fusions have been identified as targetable oncogenic drivers, a discovery that highlights the importance of deep molecular characterization for KRAS wild-type pancreatic cancers and provides a novel treatment strategy in this disease.See related article by Jones et al., p. 4674.
IFI16 Targets the Transcription Factor Sp1 to Suppress HIV-1 Transcription and Latency Reactivation
Authors: Dominik Hotter, Matteo Bosso, Kasper L. Jønsson, Christian Krapp, Christina M. Stürzel, Atze Das, Elisabeth Littwitz-Salomon, Ben Berkhout, Alina Russ, Sabine Wittmann, Thomas Gramberg, Yue Zheng, Laura J. Martins, Vicente Planelles, Martin R. Jakobsen, Beatrice H. Hahn, Ulf Dittmer, Daniel Sauter, Frank Kirchhoff
Journal: Cell Host & Microbe (2019)
Calr Vs. JAK2 Vs. MPL Mutations in the Progression of Philadelphia-Negative Myeloproliferative Neoplasms
Authors: Jie Bai, Mengyao Sheng, Wen Xing, Jiaojiao Bai, Rong Li, Jun Shi, Lei Zhang, Weiping Yuan, Feng-Chun Yang, Yuan Zhou
Journal: Blood (2017)
Abstract 13925: The Link Between Chronotropic Insufficiency and Left Atrial Dynamics in Heart Failure of Reduced and Preserve Ejection Fraction: Insights From Exercise Echocardiography Combined With Gas Exchange Analysis
Authors: Tadafumi Sugimoto, Francesco Bandera, Greta Generati, Eleonora Alfonzetti, Vincenzo Tufaro, Marco Guazzi
Journal: Circulation (2017)

Background: The hemodynamic impact of left atrial (LA) dynamics in heart failure (HF) on chronotropic response to exercise has never been studied. Aim: To identify whether chronotropic insufficienc...
FDG PET/CT in a Case of Primary Pulmonary Ewing Sarcoma
Authors: Jun Zhang, Aisheng Dong, Yong Cui, Yang Wang
Journal: Clinical Nuclear Medicine (2019)

Abstract Extraskeletal Ewing sarcoma is rare. The common locations of extraskeletal Ewing sarcoma include the paravertebral region, lower extremities, and chest wall. Primary pulmonary Ewing sarcoma is extremely rare. Because Ewing sarcoma is sensitive to specialized chemotherapy regimens, accurate diagnosis is therefore critical. The diagnosis of pulmonary Ewing sarcoma can be challenging and need immunohistochemical and cytogenetic analyses. Imaging findings of pulmonary Ewing sarcoma have been rarely reported. This report describes a case of primary pulmonary Ewing sarcoma with immunohistochemical, cytogenetic, CT, and FDG PET/CT findings.
Risk Factors for Atrial Fibrillation in People With Type 1 Diabetes: An Observational Cohort Study of 36,258 Patients From the Swedish National Diabetes Registry
Authors: Sara Hallström, Aldina Pivodic, Annika Rosengren, Arndís F. Ólafsdóttir, Ann-Marie Svensson, Marcus Lind
Journal: Diabetes Care (2019)

OBJECTIVE This study identified variables associated with increased risk of atrial fibrillation in people with type 1 diabetes. RESEARCH DESIGN AND METHODS We performed a cohort study of people with type 1 diabetes from the Swedish National Diabetes Registry followed up between 1 January 2001 and 31 December 2013. Median follow-up was 9.7 years (interquartile range 5.2–13.0). The association between potential risk factors and incident atrial fibrillation was investigated using adjusted Cox regression. To compare the impact of each risk factor, the gradient of risk per 1 SD was estimated. RESULTS In this cohort of 36,258 patients with type 1 diabetes, 749 developed atrial fibrillation during follow-up. Older age, male sex, renal complications, increased BMI and HbA1c, coronary artery disease, heart failure, and heart valve disease increased the risk of atrial fibrillation. Age, signs of renal dysfunction with macroalbuminuria, and decreasing estimated glomerular filtration rate were associated with the highest gradient of risk for atrial fibrillation. High blood pressure, severe obesity (BMI &amp;gt;35 kg/m2), and elevated levels of HbA1c (&amp;gt;9.6%) were associated with increased risk, but no associations were found with hyperlipidemia or smoking. CONCLUSIONS The most prominent risk factors for atrial fibrillation in people with type 1 diabetes were older age, cardiovascular comorbidities, and renal complications, while obesity, hypertension, and hyperglycemia had more modest affects.
Abstract 15323: Effect of a Randomized Intervention With Mobile Phone Text Messaging in Women to Achieve Ideal Cardiovascular Health: ESCI Study
Authors: Monica Acevedo, Paola Varleta, Carolina Casas-Cordero, Carlos Navarrete, Amalia Berríos
Journal: Circulation (2018)

In 2011, AHA proposed the concept of Ideal Cardiovascular Health (ICH), gathering 7 ideal behavioral and cardiovascular risk factors (CVRF) to achieve a reduction in CV morbidity and mortality of 2...
CC-122 DLBCL-001: Phase Ib Study of CC-122 Plus Rituximab in Patients with Chemo-Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Authors: Vincent Ribrag, Julio C. Chavez, Umberto Vitolo, Jason B. Kaplan, Jason C. Chandler, Armando Santoro, Paolo Corradini, Ian W. Flinn, Loretta Nastoupil, Philippe A. Cassier, Randeep Sangha, Vaishalee P. Kenkre, Ranjana H. Advani, Iris Isufi, Thomas E Witzig, Michael Petrarca, Patrick R. Hagner, Anita K. Gandhi, Xiaoling Wu, Kristen Hege, Michael Pourdehnad, John Kuruvilla
Journal: Blood (2017)
Vitamin D Supplementation and Prevention of Type 2 Diabetes
Authors: Anastassios G. Pittas, Bess Dawson-Hughes, Patricia Sheehan, James H. Ware, William C. Knowler, Vanita R. Aroda, Irwin Brodsky, Lisa Ceglia, Chhavi Chadha, Ranee Chatterjee, Cyrus Desouza, Rowena Dolor, John Foreyt, Paul Fuss, Adline Ghazi, Daniel S. Hsia, Karen C. Johnson, Sangeeta R. Kashyap, Sun Kim, Erin S. LeBlanc, Michael R. Lewis, Emilia Liao, Lisa M. Neff, Jason Nelson, Patrick O’Neil, Jean Park, Anne Peters, Lawrence S. Phillips, Richard Pratley, Philip Raskin, Neda Rasouli, David Robbins, Clifford Rosen, Ellen M. Vickery, Myrlene Staten
Journal: New England Journal of Medicine (2019)

Observational studies support an association between a low blood 25-hydroxyvitamin D level and the risk of type 2 diabetes. However, whether vitamin D supplementation lowers the risk of diabetes is unknown.We randomly assigned adults who met at least two of three glycemic criteria for prediabetes (fasting plasma glucose level, 100 to 125 mg per deciliter; plasma glucose level 2 hours after a 75-g oral glucose load, 140 to 199 mg per deciliter; and glycated hemoglobin level, 5.7 to 6.4%) and no diagnostic criteria for diabetes to receive 4000 IU per day of vitamin D3 or placebo, regardless of the baseline serum 25-hydroxyvitamin D level. The primary outcome in this time-to-event analysis was new-onset diabetes, and the trial design was event-driven, with a target number of diabetes events of 508.A total of 2423 participants underwent randomization (1211 to the vitamin D group and 1212 to the placebo group). By month 24, the mean serum 25-hydroxyvitamin D level in the vitamin D group was 54.3 ng per milliliter (from 27.7 ng per milliliter at baseline), as compared with 28.8 ng per milliliter in the placebo group (from 28.2 ng per milliliter at baseline). After a median follow-up of 2.5 years, the primary outcome of diabetes occurred in 293 participants in the vitamin D group and 323 in the placebo group (9.39 and 10.66 events per 100 person-years, respectively). The hazard ratio for vitamin D as compared with placebo was 0.88 (95% confidence interval, 0.75 to 1.04; P = 0.12). The incidence of adverse events did not differ significantly between the two groups.Among persons at high risk for type 2 diabetes not selected for vitamin D insufficiency, vitamin D3 supplementation at a dose of 4000 IU per day did not result in a significantly lower risk of diabetes than placebo. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; D2d ClinicalTrials.gov number, NCT01942694.).
Escalating Congo Ebola epidemic passes 2000 cases amid violence and suspicion
Authors: Owen Dyer
Journal: BMJ (2019)

The Ebola outbreak in the troubled north east of the Democratic Republic of the Congo has passed 2000 confirmed and probable cases, the World Health Organization has announced. The epidemic is now spreading faster than ever, as local suspicion and attacks from armed groups disable the medical response.

The 2000th case was a “sad and frustrating milestone,” said Tariq Riebl, emergency response director of the International Rescue Committee. At least 1346 people have died in the outbreak.

This is the second worst Ebola outbreak ever, though still far behind the 2014 west African epidemic that killed over 11 000 people. No other outbreak has killed over 300.

“To say that things are not going well is an understatement,” said Riebl. “It’s time the international community wakes up to the severity of this crisis. 

“We are now seeing eight to …
Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer
Authors: Shinichi Yachida, Sayaka Mizutani, Hirotsugu Shiroma, Satoshi Shiba, Takeshi Nakajima, Taku Sakamoto, Hikaru Watanabe, Keigo Masuda, Yuichiro Nishimoto, Masaru Kubo, Fumie Hosoda, Hirofumi Rokutan, Minori Matsumoto, Hiroyuki Takamaru, Masayoshi Yamada, Takahisa Matsuda, Motoki Iwasaki, Taiki Yamaji, Tatsuo Yachida, Tomoyoshi Soga, Ken Kurokawa, Atsushi Toyoda, Yoshitoshi Ogura, Tetsuya Hayashi, Masanori Hatakeyama, Hitoshi Nakagama, Yutaka Saito, Shinji Fukuda, Tatsuhiro Shibata, Takuji Yamada
Journal: Nature Medicine (2019)
Reconsidering the Consequences of Using Race to Estimate Kidney Function
Authors: Nwamaka Denise Eneanya, Wei Yang, Peter Philip Reese
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Radionuclide Therapy With 177Lu-PSMA in a Case of Metastatic Adenoid Cystic Carcinoma of the Parotid
Authors: Duygu Has Simsek, Serkan Kuyumcu, Fulya Yaman Agaoglu, Seher Nilgun Unal
Journal: Clinical Nuclear Medicine (2019)

Abstract In vivo prostate-specific membrane antigen (PSMA) overexpression creates an opportunity for PSMA-directed theranostic approach in adenoid cystic carcinoma of the parotid. Herein, we illustrate a patient with metastatic PSMA-directed theranostic approach in adenoid cystic carcinoma of the parotid who had intense PSMA uptake on metastatic lesions, followed by radionuclide therapy with 177 Lu-PSMA.
Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML
Authors: Riikka Karjalainen, Minxia Liu, Ashwini Kumar, Liye He, Disha Malani, Alun Parsons, Mika Kontro, Olli Kallioniemi, Kimmo Porkka, Caroline A. Heckman
Journal: Leukemia (2019)
Assessment of Anti-Bacterial Antibodies in Multiple Myeloma Patients at Disease Presentation and in Response to Therapy: Implication for Patient Management
Authors: Ilaria Chicca, Jennifer Lj Heaney, Gulnaz Iqbal, Stella Bowcock, Tim Planche, Jill Wood, Kerry Raynes, Peter Hawkey, Guy Pratt, Kwee Yong, Helen Higgins, Janet Dunn, Mark T Drayson
Journal: Blood (2017)
Abstract 16978: A History of GI Bleeding is Associated With Increased Risk of Subsequent Bleeding, but Not Stroke: Insights From the ARISTOTLE Trial
Authors: David Garcia, Lisa Wruck, Raffaele De Caterina, Daniel Wojdyla, Sigrun Halvorsen, Christopher B Granger, Elaine M Hylek, Claes Held, Michael Hanna, Lars Wallentin, John H Alexander, Renato D Lopes
Journal: Circulation (2016)

Background: In patients with atrial fibrillation (AF), a history of gastrointestinal bleeding (GIB) may impact decisions about anticoagulation treatment. Methods: Using data from ARISTOTLE, we anal...